Dopamine transporter (DAT) scan
Evidence-based neurology checklist on dopamine transporter (dat) scan: Indications To evaluate clinically uncertain Parkinsonian syndromes (CUPS) To differentiate mono-symptomatic tremors from early Parkinson’s disease To exclude Parkinsonian syndromes without nigrostriatal dysfunction Disorders…
Indications
- To evaluate clinically uncertain Parkinsonian syndromes (CUPS)
- To differentiate mono-symptomatic tremors from early Parkinson’s disease
- To exclude Parkinsonian syndromes without nigrostriatal dysfunction
Disorders causing abnormal DAT scan uptake
Conditions with normal DAT scan uptake
Benefit
References
- Kupsch AR, Bajaj N, Weiland F, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. JNNP 2012; 83:620-628.
- Catafau AM, Tolosa E; DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord 2004; 19:1175e82.
- Seifert KD, Wiener JI. The impact of DaTscan on the diagnosis and management of movement disorders: a retrospective study. Am J Neurodegener Dis 2013; 2:29-34.
- Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. JNNP 2010; 81:5-12.
- Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007; 22:1229-1238.
- And 2 more. Subscribe to see the full list
